Use of Enalapril to Prevent Myointimal Hyperplasia in Arm's Arteriovenous Fistula for Hemodialysis Access

End-point: Evaluate the effect of Enalapril in preventing Myointimal Hyperplasia (MIH) in arm's arteriovenous fistula (AVF) for hemodialysis access. Method: Inclusion criteria consisted on patients with no ACEI, or angiotensin II receptor blockers (ARB) treatment, or no intake up to 3 months before procedure, declared suitable for AVF access, and having thrill and bruit after AVF construction procedure. Under these criteria, we selected eighty-eight patients and assigned them randomly in case group and control group. Case group received Enalapril 48 hours before AVF construction procedure and during study. We did evaluations of efferent vein diameter, myointimal complex, and flow velocities with Doppler Ultrasound (DU) during six weeks after procedure. MIH risk factors according to medical history and obtained data analysis were performed using student test. Results: After medical history analysis, the main MIH risk factors presented were diabetes, hypertension and active smoking p=0.05. Within control group, MIH was higher as three patients had AVF failure vs one patient in case group, the Enalapril group. Conclusion: We found no statistical difference in both groups (p=0.637).